STOKStoke Therapeutics, Inc.
Earnings
When Stoke Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
35 quarters. Mar 31, 2018 to Sep 30, 2026. USD.
Next results · Q4 2026Projected
Jan 11, after the close
Mon, Jan 11, 2027in 55 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Mar 8 – 26
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $1.40M
- Revenue, change from a year earlier: Q3 2026 +5.9%, Q2 2026 −32.5%, Q1 2026 −96.1%, Q4 2025 −93.8%
- Net income
- -$57.93M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Latest results
- Revenue
- $11.26M
- +5.9%
- Net income
- -$73.64M
- N/M
- EPS
- -$1.08
- N/M
- Revenue
- $9.33M
- −32.5%
- Net income
- -$61.62M
- N/M
- EPS
- -$0.93
- N/M
- Revenue
- $6.23M
- −96.1%
- Net income
- -$50.00M
- N/M
- EPS
- -$0.79
- N/M
- Revenue
- $1.40M
- −93.8%
- Net income
- -$57.93M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Oct 29, 2026 · after-hours | Nov 3, 2026 | 34 d | 10-Q | $11.26M | +5.9% | -$1.08 | 0.3% | |
| Q2 2026 | Jun 30, 2026 | Aug 3, 2026 · after-hours | Aug 3, 2026 | 34 d | 10-Q | $9.33M | −32.5% | -$0.93 | +7.0% | |
| Q1 2026 | Mar 31, 2026 | May 7, 2026 · after-hours | May 7, 2026 | 37 d | 10-Q | $6.23M | −96.1% | -$0.79 | +0.4% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Jan 12, 2026 · pre-market | Mar 16, 2026 | 75 d | 10-K | $1.40M | −93.8% | — | 10.4% | |
| Q3 2025 | Sep 30, 2025 | Nov 4, 2025 · after-hours | Nov 4, 2025 | 35 d | 10-Q | $10.63M | +117.2% | -$0.65 | 10.0% | |
| Q2 2025 | Jun 30, 2025 | Aug 12, 2025 · after-hours | Aug 12, 2025 | 43 d | 10-Q | $13.82M | +186.0% | -$0.40 | +25.0% | |
| Q1 2025 | Mar 31, 2025 | May 13, 2025 · pre-market | May 13, 2025 | 43 d | 10-Q | $158.57M | +3,661.1% | $1.90 | 7.6% | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | Mar 18, 2025 · pre-market | Mar 18, 2025 | 77 d | 10-K | $22.61M | +707.4% | — | 1.6% | |
| Q3 2024 | Sep 30, 2024 | Nov 5, 2024 · pre-market | Nov 5, 2024 | 36 d | 10-Q | $4.89M | +47.9% | -$0.47 | 0.2% | |
| Q2 2024 | Jun 30, 2024 | Aug 7, 2024 · pre-market | Aug 7, 2024 | 38 d | 10-Q | $4.83M | N/M | -$0.46 | — | |
| Q1 2024 | Mar 31, 2024 | May 6, 2024 · pre-market | May 6, 2024 | 36 d | 10-Q | $4.22M | −18.2% | -$0.57 | — | |
| FY 2023 | ||||||||||
| Q4 2023derived | Dec 31, 2023 | Mar 25, 2024 · after-hours | Mar 25, 2024 | 85 d | 10-K | $2.80M | −14.3% | — | +58.3% | |
| Q3 2023 | Sep 30, 2023 | Nov 7, 2023 · pre-market | Nov 7, 2023 | 38 d | 10-Q | $3.31M | +13.9% | -$0.55 | +7.0% | |
| Q2 2023 | Jun 30, 2023 | Aug 7, 2023 · pre-market | Aug 7, 2023 | 38 d | 10-Q | -$2.48M | N/M | -$0.69 | 4.4% | |
| Q1 2023 | Mar 31, 2023 | May 4, 2023 · pre-market | May 4, 2023 | 34 d | 10-Q | $5.15M | +71.7% | -$0.53 | — | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Mar 6, 2023 · pre-market | Mar 6, 2023 | 65 d | 10-K | $3.27M | — | — | — | |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 · pre-market | Nov 14, 2022 | 45 d | 10-Q | $2.91M | — | -$0.66 | 25.3% | |
| Q2 2022 | Jun 30, 2022 | Aug 8, 2022 · pre-market | Aug 8, 2022 | 39 d | 10-Q | $3.23M | — | -$0.63 | +36.8% | |
| Q1 2022 | Mar 31, 2022 | May 10, 2022 · pre-market | May 10, 2022 | 40 d | 10-Q | $3.00M | — | -$0.66 | +8.0% | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Mar 10, 2022 · pre-market | Mar 10, 2022 | 69 d | 10-K | — | — | — | — | |
| Q3 2021 | Sep 30, 2021 | Nov 8, 2021 · pre-market | Nov 8, 2021 | 39 d | 10-Q | — | — | -$0.60 | — | |
| Q2 2021 | Jun 30, 2021 | Aug 10, 2021 · pre-market | Aug 10, 2021 | 41 d | 10-Q | — | — | -$0.60 | — | |
| Q1 2021 | Mar 31, 2021 | May 10, 2021 · pre-market | May 10, 2021 | 40 d | 10-Q | — | — | -$0.46 | — | |
| FY 2020 | ||||||||||
| Q4 2020 | Dec 31, 2020 | Mar 9, 2021 · pre-market | Mar 9, 2021 | 68 d | 10-K | — | — | -$0.42 | — | |
| Q3 2020 | Sep 30, 2020 | Nov 12, 2020 · pre-market | Nov 12, 2020 | 43 d | 10-Q | — | — | -$0.41 | 0.5% | |
| Q2 2020 | Jun 30, 2020 | Aug 10, 2020 · pre-market | Aug 10, 2020 | 41 d | 10-Q | — | — | -$0.39 | +6.2% | |
| Q1 2020 | Mar 31, 2020 | May 15, 2020 · pre-market | May 15, 2020 | 45 d | 10-Q | — | — | -$0.34 | +15.3% | |
| FY 2019 | ||||||||||
| Q4 2019 | Dec 31, 2019 | Mar 23, 2020 · pre-market | Mar 23, 2020 | 83 d | 10-K | — | — | -$0.31 | 3.9% | |
| Q3 2019 | Sep 30, 2019 | Nov 12, 2019 · pre-market | Nov 12, 2019 | 43 d | 10-Q | — | — | -$0.26 | 8.0% | |
| Q2 2019 | Jun 30, 2019 | Aug 14, 2019 · pre-market | Aug 14, 2019 | 45 d | 10-Q | — | — | -$1.54 | +6.4% | |
| Q1 2019 | Mar 31, 2019 | — | — | — | — | — | — | -$6.89 | — | |
| FY 2018 | ||||||||||
| Q4 2018 | Dec 31, 2018 | — | — | — | — | — | — | -$6.05 | — | |
| Q3 2018 | Sep 30, 2018 | — | — | — | — | — | — | -$4.75 | — | |
| Q2 2018 | Jun 30, 2018 | — | — | — | — | — | — | -$4.36 | — | |
| Q1 2018 | Mar 31, 2018 | — | — | — | — | — | — | -$2.78 | — | |
Earlier years, FY 2018 to FY 2023The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Stoke Therapeutics, Inc. · CIK 1623526 · Engraved from SEC EDGAR